quantisnow
FeedTopReportsPricing
⌘K
Live feed
18:11:00·45d
INSIDERFiling
Novavax Inc. logo

Amendment: SEC Form 4 filed by EVP, Research & Development Draghia-Akli Ruxandra

NVAX· Novavax Inc.
Health Care
Original source

Companies

  • NVAX
    Novavax Inc.
    Health Care

Recent analyst ratings

  • Oct 24UpdateCantor Fitzgerald$18.00
  • Aug 28UpdateH.C. Wainwright$10.00
  • Aug 20UpdateBofA Securities$7.00
  • Jun 17UpdateCitigroup$6.00
  • Feb 28UpdateBTIG Research$19.00
  • Jul 30UpdateJP Morgan$8.00

Related

  • INSIDER7d
    SEC Form 4 filed by Walker Robert Edward
  • INSIDER7d
    SEC Form 3 filed by new insider Walker Robert Edward
  • SEC15d
    Amendment: SEC Form SCHEDULE 13D/A filed by Novavax Inc.
  • PR24d
    Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Novavax Inc.
  • INSIDER42d
    Director Shiver John W. converted options into 7,947 shares (SEC Form 4)
  • INSIDER45d
    EVP, CFO and Treasurer Kelly James Patrick converted options into 12,223 shares and covered exercise/tax liability with 5,904 shares, increasing direct ownership by 5% to 130,599 units (SEC Form 4)
  • INSIDER45d
    Amendment: SEC Form 4 filed by EVP, CFO and Treasurer Kelly James Patrick
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022